Quince Therapeutics names Leone Patterson audit, compensation committee chair in board overhaul

By Public Technologies
  • Quince Therapeutics disclosed conditional resignations from directors June Bray, David Lamond, Christopher Senner, effective two business days post-Oct. 6 meeting.
  • Departures hinge on shareholder approval of stock issuance tied to Series C Non-Voting Convertible Preferred Stock conversions and related warrants.
  • Board slated to add Catherine Bonuccelli, principal at CMB Life Sciences Consulting and former Bellus Health chief medical officer.
  • Leone Patterson, former Zymeworks EVP, chief business officer, CFO, set to join as audit and compensation committee chair.
  • James Valentine, Hyman, Phelps & McNamara director and former FDA staffer, named governance chair; Drayton Wise, ex-Insmed chief commercial officer, to join.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-411260), on October 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.